Leap Therapeutics, Inc. financial data

Symbol
LPTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
47 Thorndike Street, Suite B1 1, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Dekkun Corp (to 1/7/2011)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 495 % -37%
Debt-to-equity 24.8 % +34.3%
Return On Equity -116 % +12.8%
Return On Assets -93.2 % -2.26%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.3M shares +49.9%
Common Stock, Shares, Outstanding 38.3M shares +49.7%
Entity Public Float 77.7M USD -17.2%
Common Stock, Value, Issued 38K USD +46.2%
Weighted Average Number of Shares Outstanding, Basic 41.2M shares +52.7%
Weighted Average Number of Shares Outstanding, Diluted 41.2M shares +52.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 55.8M USD -23.1%
General and Administrative Expense 13M USD -4.51%
Operating Income (Loss) -68.8M USD +20.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -17.5M USD -27.5%
Income Tax Expense (Benefit) 708K USD
Net Income (Loss) Attributable to Parent -64.6M USD +20.3%
Earnings Per Share, Basic -0.79 USD/shares +88%
Earnings Per Share, Diluted -0.79 USD/shares +88%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 62.8M USD -22.2%
Assets, Current 63.8M USD -22%
Deferred Income Tax Assets, Net 142K USD -16%
Property, Plant and Equipment, Net 5K USD -75%
Operating Lease, Right-of-Use Asset 370K USD +1.93%
Other Assets, Noncurrent 15K USD -80%
Assets 65M USD -21.7%
Accounts Payable, Current 5.95M USD +0.8%
Employee-related Liabilities, Current 2.72M USD +11.6%
Accrued Liabilities, Current 9.05M USD +89.7%
Liabilities, Current 16.1M USD +45.8%
Operating Lease, Liability, Noncurrent 39K USD +2.63%
Liabilities 16.1M USD +45.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 6K USD -99.2%
Retained Earnings (Accumulated Deficit) -452M USD -16.7%
Stockholders' Equity Attributable to Parent 49M USD -32%
Liabilities and Equity 65M USD -21.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.5M USD -22.2%
Net Cash Provided by (Used in) Financing Activities -210K USD -102%
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 38.3M shares +49.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -15.7M USD -143%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 62.8M USD -22.2%
Deferred Tax Assets, Valuation Allowance 38.2M USD -52.8%
Deferred Tax Assets, Gross 38.2M USD -52.8%
Operating Lease, Liability 376K USD +1.9%
Depreciation 5K USD +25%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -65.3M USD +19.3%
Lessee, Operating Lease, Liability, to be Paid 390K USD +2.36%
Property, Plant and Equipment, Gross 226K USD 0%
Operating Lease, Liability, Current 376K USD +1.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 268K USD -40.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 273K USD +142%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14K USD +16.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 268K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 501M USD +9.28%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 54K USD +31.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares